Recent observations on the interaction of plasma oestrogen levels with the preventive effect of the aromatase inhibitor anastrozole make it timely to consider the development of oestrogen-targeted prevention of breast cancer and the evidence upon which that development was made. Here, CYP19A1 is linked to breast cancer.